An inflammatory antibody called Ter119 reduces inflammation and arthritis in numerous mouse models and autoimmune ailments. Developed at Keenan Research Centre for Biomedical Science (KRCBS), this new approach holds real potential.
As published in Science Translational Medicine, the KRCBS team has discovered a new channel to pursue autoimmune disease treatments. An antibody (proteins generated by immune system to stop invaders, such as bacteria and virus) that seeks out red blood cells for annihilation.
Ter119 is a lab example of a treatment that already exists for patients with immune thrombocytopenic purpura (ITP), which is a bleeding disorder in which the immune system destroys platelets. The treatment is known as Rh(D) Immunoglobulin or Anti-D.
Using lab models, the Canadian team, housed in St. Michael’s Hospital, suggests that in addition to Ter119’s therapeutic effects in models of ITP, it also had positive effects on three models of arthritis and transfusion-related acute lung injury.
The researchers wanted to ensure consistency of findings, so they pursued tests in multiple models of arthritis. They did note in their press release that the research was all based on acute models and that in the real world, most patients have chronic autoimmune disorders.
Who is Keenan Research Centre for Biomedical Science (KRCBS)?
Located within St. Michael’s Hospital, KRCBS is home to basic science and translational research. The researchers target common and high-burden illnesses that are important to patient’s and strive to make discoveries that will improve patient’s lives.
Research at St. Michael’s Hospital is comprised of two main components—KRCBS (basic and translational) and La Ka Shing Knowledge Institute focusing on clinical and health services research. The entire group is fully affiliated with the University of Canada, the largest research entity in Canada.
Dr. Alan Lazarus, co-director of the Hematology-Immunology Translational Research Collaboration
Call to Action: Are you interested in translational research for autoimmune disease-including arthritis? Then it makes sense to follow this novel antibody research at St. Michael’s KRCBS. Interested in partnering with KRCBS? Contact the St. Michael’s Technology Transfer Division, led by Samar Saneinejad, Director, Strategic & Commercialization, Office of the Vice-President, Research & Innovation at SanneinejadS@smh.com, or contact TrialSite News to learn about its’ TrialSite Network R&D matching service.